TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06463028: Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Sponsor: Faeth Therapeutics · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,049,200

Rescue Site Savings

+$2,032,800

Unlock Full NCT06463028 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06463028 Rescue Dossier →